I can absolutely submit some research and opinion pieces from the patients and doctors if you would like. I believe they're very helpful and outline more patient-centred cases in which both patients and health care professionals, as well as families, have been helped by this.
I will just add a bit more on the use of psilocybin and what we've seen in close to 100 treatments that our organization has helped facilitate with doctors such as Dr. Val Masuda.
Psilocybin, the compound, alone does not alleviate much of the end-of-life distress. It's commonly referred to as that, but it is the combination of anxiety, depression and hopelessness that a patient faces when they're told that they're going to die. Again, this does not affect every cancer patient, but some of the literature reviews we've done—which we will also try to include—show that about 2,800 Canadians every year fall into this category of treatment-resistant depression or anxiety due to an end-of-life diagnosis.
What the psilocybin does, coupled with psychotherapy, which is what you're referring to and what Johns Hopkins was referring to, when it is conducted with clinicians in a safe space—and that space can be the patient's home, where many of the treatments have been done—is to aid in the psychotherapeutic process. It allows people to let their guard down. In many cases, it allows the therapist to actually do the work that they need to do.
For many people the psychotherapeutic process is hindered by lies that people tell themselves and by fears. In many cases, the patients coming out of these experiences are reporting that they are no longer afraid of death or that they feel a oneness with the universe. It is essentially years of psychotherapy packed into a single session with the help of medicine.